Yuhan Corporation is holding a corporate presentation (Non-Deal Roadshow) for domestic institutional investors from August 19 to 21, focusing on its performance and new drug pipeline to outline future growth strategies. The company aims to enhance its corporate value by expanding communication with both institutional and individual investors.
According to Yuhan Corporation on August 20, the presentation will highlight the growth potential of its existing pharmaceutical business and the global achievements of its new drug initiatives. The company plans to discuss stable performance metrics, including revenue growth and increased demand in the pharmaceutical sector, as well as overseas business opportunities arising from changes in the active pharmaceutical ingredient (API) market supply chain. Investors will also be updated on the prescription expansion of Lazertinib (Lazara), which is currently seeing increased sales in global markets.
The growth strategy for its research and development (R&D) in new drugs will also be a key focus. Yuhan Corporation intends to implement tailored business development strategies to enhance the commercialization of its pipeline, while diversifying its business model through collaborative clinical research and Newco approaches.
The company is also strengthening its investor engagement activities. Starting this year, it has produced investor relations materials in Korean, English, Japanese, and Chinese to make company information more accessible to stakeholders, including overseas investors. Following the NDR for institutional investors, Yuhan Corporation plans to visit personal banking centers at securities firms in the metropolitan area and provinces to continue engaging with individual investors.
Additionally, Yuhan Corporation is pursuing a shareholder return policy. Last month, the board of directors resolved to retire all of its treasury shares, amounting to 425.3 billion won, including common and preferred stocks. After the retirement, the number of issued shares will decrease from approximately 80.82 million to 74.76 million, a reduction of 7.5%.
A Yuhan Corporation representative stated, "Through this NDR, we will transparently communicate the company's growth direction and business strategies to investors. We will continue to expand our communication with the market in various ways to enhance corporate value and trust in our information."
Meanwhile, Yuhan Corporation is running a 'Brand Week' promotion on its official online mall, Budal Market, offering concentrated discounts on one selected brand each week until September 6. This promotion features Yuhan Corporation's major consumer brands, ranging from health supplements to household goods and pet products, showcased weekly. Special prices for each brand will open on Mondays and close on Sundays, with new brands and products introduced each week.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.